An inorganic complex that inhibits Mycobacterium tuberculosis enoyl reductase as a prototype of a new class of chemotherapeutic agents to treat tuberculosis

AUTOR(ES)

Basso, Luiz A., Schneider, Cristopher Z., Santos, Anderson J. A. B. dos, Santos Jr, André A. dos, Campos, Maria M., Souto, André A., Santos, Diógenes S.

FONTE

Journal of the Brazilian Chemical Society

DATA DE PUBLICAÇÃO

2010

RESUMO

Descrevemos a atividade inibitória do IQG607, pentaciano(isoniazida)ferrato(II), frente a cepas de Mycobacterium tuberculosis tanto resistentes quanto sensíveis à isoniazida, assim como a toxicidade oral e a adaptação da síntese química do IQG607 para reatores maiores. O IQG607 representa um potencial agente quimioterápico que inibe um alvo molecular definido.

Documentos Relacionados

• A New Method of Determining the Sensitivity of M. tuberculosis to Chemotherapeutic Agents
• Kinetic and equilibrium mechanisms of substrate binding to Mycobacterium tuberculosis enoyl reductase: implications to function-based antitubercular agent design
• Synthesis, Inhibition of Mycobacterium tuberculosis Enoyl-acyl Carrier Protein Reductase and Antimycobacterial Activity of Novel Pentacyanoferrate(II)-isonicotinoylhydrazones
• A new evolutionary scenario for the Mycobacterium tuberculosis complex
• The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance